NO20070996L - Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser - Google Patents
Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelserInfo
- Publication number
- NO20070996L NO20070996L NO20070996A NO20070996A NO20070996L NO 20070996 L NO20070996 L NO 20070996L NO 20070996 A NO20070996 A NO 20070996A NO 20070996 A NO20070996 A NO 20070996A NO 20070996 L NO20070996 L NO 20070996L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- treating
- patients
- disorders
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Den foreliggende oppfinnelsen tilveiebringer fremgangsmåter for å redusere eller å opprettholde kroppsvekt og/eller kroppsfett i pasienter, f. eks. mennesker og dyr, for eksempel i behandlingen av overvekt- eller fedmepasienter, eller som en måte for å produsere magrere kjøtt i husdyr, f. eks. storfe, kylling, gris, alene eller i kombinasjon med annet terapeutisk middel; fremgangsmåter for å behandle diabetes og/eller glukoseintoleranse; og fremgangsmåter for å behandle metabolske syndromlidelser i pasienter som trenger det, ved å gi et CCR2 terapeutisk middel, kit for de ovenfor identifiserte terapeutiske anvendelsene og fremgangsmåter for å identifisere CCR2 terapeutiske midler for å behandle de ovenfor beskrevne terapeutiske anvendelsene.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59268304P | 2004-07-30 | 2004-07-30 | |
PCT/IB2005/002162 WO2006013427A2 (en) | 2004-07-30 | 2005-07-18 | Treatment of ccr2 mediated diseases or disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20070996L true NO20070996L (no) | 2007-04-23 |
Family
ID=35207829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20070996A NO20070996L (no) | 2004-07-30 | 2007-02-21 | Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090196823A1 (no) |
EP (1) | EP1778285A2 (no) |
JP (1) | JP2008508253A (no) |
KR (1) | KR20080044360A (no) |
CN (1) | CN101005855A (no) |
AU (1) | AU2005268545A1 (no) |
BR (1) | BRPI0513953A (no) |
CA (1) | CA2575612A1 (no) |
IL (1) | IL180675A0 (no) |
MX (1) | MX2007001204A (no) |
NO (1) | NO20070996L (no) |
RU (1) | RU2007103332A (no) |
WO (1) | WO2006013427A2 (no) |
ZA (1) | ZA200700823B (no) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7671062B2 (en) | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
US7687508B2 (en) | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
US7629351B2 (en) | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
EP2321351B1 (en) | 2008-08-18 | 2017-11-01 | Pfizer Inc. | Antibodies to ccr2 |
US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
US9726666B2 (en) | 2011-06-13 | 2017-08-08 | Tla Targeted Immunotherapies Ab | Diagnosing and treating inflammatory diseases |
US9434766B2 (en) * | 2011-06-27 | 2016-09-06 | Universite Pierre Et Marie Curie (Paris 6) | CCR2 antagonist peptides |
WO2022235440A1 (en) * | 2021-04-21 | 2022-11-10 | The United States Government As Represented By The Department Of Veterans Affairs | Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
FR2792837B1 (fr) * | 1999-04-29 | 2001-07-13 | Centre Nat Rech Scient | Medicaments utiles pour le traitement des troubles de la regulation de la masse adipeuse et des maladies associees aux troubles de la production de leptine |
AU2003235097A1 (en) * | 2002-04-24 | 2003-11-10 | Takeda Pharmaceutical Company Limited | Use of compounds having ccr antagonism |
JP2007523871A (ja) * | 2003-07-15 | 2007-08-23 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の7および8員複素環式シクロペンチルベンジルアミドモジュレーター |
US7576089B2 (en) * | 2003-12-18 | 2009-08-18 | Incyte Corporation | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors |
-
2005
- 2005-07-18 MX MX2007001204A patent/MX2007001204A/es unknown
- 2005-07-18 CN CNA2005800276608A patent/CN101005855A/zh active Pending
- 2005-07-18 JP JP2007523167A patent/JP2008508253A/ja not_active Withdrawn
- 2005-07-18 BR BRPI0513953-8A patent/BRPI0513953A/pt not_active IP Right Cessation
- 2005-07-18 AU AU2005268545A patent/AU2005268545A1/en not_active Abandoned
- 2005-07-18 CA CA002575612A patent/CA2575612A1/en not_active Abandoned
- 2005-07-18 WO PCT/IB2005/002162 patent/WO2006013427A2/en active Application Filing
- 2005-07-18 RU RU2007103332/14A patent/RU2007103332A/ru not_active Application Discontinuation
- 2005-07-18 KR KR1020087010937A patent/KR20080044360A/ko not_active Application Discontinuation
- 2005-07-18 EP EP05777347A patent/EP1778285A2/en not_active Withdrawn
- 2005-09-16 US US11/658,989 patent/US20090196823A1/en not_active Abandoned
-
2007
- 2007-01-11 IL IL180675A patent/IL180675A0/en unknown
- 2007-01-29 ZA ZA200700823A patent/ZA200700823B/xx unknown
- 2007-02-21 NO NO20070996A patent/NO20070996L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2006013427A3 (en) | 2006-06-08 |
US20090196823A1 (en) | 2009-08-06 |
MX2007001204A (es) | 2007-03-23 |
BRPI0513953A (pt) | 2008-05-20 |
KR20080044360A (ko) | 2008-05-20 |
RU2007103332A (ru) | 2008-08-10 |
EP1778285A2 (en) | 2007-05-02 |
AU2005268545A1 (en) | 2006-02-09 |
ZA200700823B (en) | 2008-10-29 |
CN101005855A (zh) | 2007-07-25 |
JP2008508253A (ja) | 2008-03-21 |
CA2575612A1 (en) | 2006-02-09 |
IL180675A0 (en) | 2007-06-03 |
WO2006013427A2 (en) | 2006-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070996L (no) | Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser | |
TW200612957A (en) | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions | |
UA102669C2 (en) | Use of dpp-iv inhibitors | |
NO20074943L (no) | Roflumilast for behandlingen av diabetes mellitus | |
MX2010004074A (es) | Combinacion 059. | |
EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
ATE432693T1 (de) | Kombinationstherapie zur behandlung von diabetes und dadurch bedingten leiden sowie zur behandlung von mittels erhöhung des glp-1-spiegels im blut verbesserten leiden | |
DE602005013811D1 (de) | Behandlung von fettsucht und verbundenen erkrankungen | |
WO2005116088A3 (en) | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells | |
WO2007089617A3 (en) | Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith | |
SG158112A1 (en) | Hepatocyte growth factor (hgf) binding proteins | |
BRPI0609393B8 (pt) | usos de um composto 11-desóxi-prostaglandina | |
ATE453642T1 (de) | Substituierte phenylaminopyrimidine | |
NO20076121L (no) | Behandlinger for kardiovaskulaer sykdom | |
DE502006006466D1 (de) | Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen | |
WO2006114105A3 (en) | Use of modified factor vii for treating bleeding | |
MXPA06012143A (es) | Arilsulfonamidas y usos relacionados con las mismas. | |
MX2007010484A (es) | Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2. | |
BRPI0712561B8 (pt) | Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida | |
BRPI0415781A (pt) | método para o tratamento de diabetes em um paciente e kit farmacêutico | |
BRPI0610454B8 (pt) | método para tratar ou prevenir diabetes tipo-2 | |
TW200738255A (en) | Methods of regulating renalase (Monoamine Oxidase C) | |
DE602008004556D1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
WO2006083667A3 (en) | Treatment of oxygen induced inflammatory tissue injury | |
GB2445882A (en) | Prophylactic and therapeutic agents and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |